#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Apr 13, 2026 Episode Page ↗
Overview

In this AMA, Peter Attia explores gray-market peptides, providing a clear framework for evaluating any peptide or drug. He distinguishes FDA-approved therapeutics from loosely regulated 'biohacking' peptides, examining evidence, safety, and regulatory challenges.

At a Glance
5 Insights
22m 1s Duration
13 Topics
5 Concepts

Deep Dive Analysis

Defining Peptides: Basic Biology and Function

Distinguishing Peptides: FDA-Approved vs. Gray Market

Framework for Evaluating Any Drug or Peptide

Categorizing Peptides into Four Buckets

Introduction to Peptide Case Studies

SS-31: Mechanism, Claims, and Safety

Melanotan-II: Receptor Activity and Side Effects

CJC-1295: Growth Hormone Signaling and Dosing

BPC-157: Origin, Mechanisms, and Evidence

Role of Patents and Incentives in Drug Development

Gray Market Operations and Regulatory Oversight

Challenges with Oral Peptides and Absorption

Future of Peptide Therapeutics and Potential Expansion

Peptide

A peptide is a short chain of amino acids, typically up to 60-100, that are naturally produced in the body and serve essential functions as signaling molecules, neurotransmitters, and antioxidants. Examples include endorphins, insulin, and GLP-1.

FDA-Approved Peptide Therapeutics

These are peptide molecules, like insulin or GLP-1 drugs, that have undergone rigorous testing and received official approval from the FDA for specific medical indications, ensuring their safety and efficacy for human use.

Gray Market Peptides

Often referred to as 'biohacking' peptides, these are various therapeutic compounds touted for benefits like longevity, beauty, or tissue healing, but they lack FDA approval and are typically administered via injection, sold as 'research use only'.

Mechanism of Action

This refers to a defined course of mechanistic steps that logically lead to an intended effect of a drug or supplement. A clear mechanism is a critical requirement for FDA approval, with very few approved drugs lacking this understanding.

Research Use Only (RUO)

A designation used for gray market peptides, indicating that they are not approved for human use. While their sale isn't technically illegal under this label, it's widely understood that these compounds are being used by people despite the lack of regulatory oversight.

?
What are peptides and how are they used in the body?

Peptides are short chains of amino acids that the body naturally produces, acting as signaling molecules, neurotransmitters, and more. They can also be synthetically produced to mimic these natural functions for therapeutic purposes, like insulin.

?
How do 'biohacking' peptides differ from FDA-approved peptide therapeutics?

FDA-approved peptides have undergone rigorous testing and are approved for specific medical uses, while 'biohacking' peptides are unregulated, often sold on the gray market, and lack scientific consensus on their efficacy and safety for human use.

?
What core questions should one ask before taking any drug or peptide?

You should ask if there's a viable mechanism of action, what is known about its safety and efficacy in humans, how to weigh its risks against benefits, and if there are any legitimate, approved alternatives available.

?
Why is a clear mechanism of action important for evaluating a drug or supplement?

A clear mechanism of action provides a defined course of mechanistic steps that logically lead to an intended effect, and its absence should lead to skepticism, as less than 3% of FDA-approved drugs lack a known mechanism.

?
Why are many popular peptides sold on the gray market?

Many popular peptides are sold on the gray market because they lack FDA approval for human use, often marketed as 'research use only' to circumvent strict regulatory oversight, despite being widely used by individuals.

1. Demand Clear Mechanism of Action

Be highly skeptical of any drug or supplement if its mechanism of action is not clearly defined, as over 97% of FDA-approved drugs have a known, defined course of mechanistic steps.

2. Weigh Risks Against Benefits

Always carefully weigh the potential risks and side effects against the intended benefits of any substance, reserving higher-risk interventions for situations where the risk of not taking action is sufficiently high.

3. Prioritize Approved Alternatives

Before considering gray market peptides, investigate if legitimate, FDA-approved alternatives exist that might offer a better-understood risk and benefit profile for your intended purpose.

4. Beware Shifting Benefit Claims

Be wary of peptides whose alleged benefits frequently change or expand over time, as this ‘shifting goalposts’ behavior can indicate a lack of genuine efficacy and a fabricated narrative.

5. Understand ‘Research Use Only’

Recognize that the ‘research use only’ designation for gray market peptides means they are not approved for human consumption, despite being widely used by people, and lack regulatory oversight for human safety.

If there's no mechanism of action, you should be very skeptical of a drug or supplement.

Peter Attia

Nobody would ever suggest you just take antibiotics willy-nilly. That would not make sense to ward off any potential bacteria in the room.

Peter Attia

We don't do anything in moderation on this podcast, except for moderation.

Peter Attia

Framework for Evaluating Any Drug or Peptide

Peter Attia
  1. Is there a viable mechanism of action that logically leads to an intended effect?
  2. What do we know about the downstream effects and efficacy of this in healthy individuals or the target patient population?
  3. What do we know about the safety profile in animals and, eventually, in humans, considering dose and usage patterns?
  4. How do the potential risks of side effects weigh against the intended benefits of the drug?
  5. Are there legitimate, FDA-approved alternatives available for the intended purpose?

Four Buckets for Peptide Evaluation

Peter Attia
  1. Bucket 1 (No Compelling Case): No viable mechanism of action, no human data or negative human data, and frequently shifting claims for alleged benefits.
  2. Bucket 2 (Abandoned Clinical Trials): Has a viable mechanism, but never entered or was abandoned in human clinical trials, with no continued interest from pharmaceutical companies.
  3. Bucket 3 (In Trials/Approved for Other Uses): Has a viable mechanism, may be in human clinical trials or approved for indications other than the popular use, with safety and efficacy data (though not necessarily for the specific popular use), and no approved version for the current popular use.
  4. Bucket 4 (Stolen FDA-Approved Drugs): Peptides sold as exact replicas of approved drugs, but illegally via 'research purposes only' means.
Less than 3%
Percentage of FDA-approved drugs with unknown mechanism of action This includes both prescription and over-the-counter drugs, highlighting the rarity of approved drugs without a defined mechanism.